International Journal of Endocrinology and Metabolism International Journal of Endocrinology and Metabolism Int J Endocrinol Metab http://www.endometabol.com 1726-913X 1726-9148 10.5812/ijem en jalali 2017 5 28 gregorian 2017 5 28 10 4
en 10.5812/ijem.7929 Obesity Dilemma: Are There Enough Bariatric Surgeons? Obesity Dilemma: Are There Enough Bariatric Surgeons? editorial editorial Obesity;Diabetes Mellituss Type2 Obesity;Diabetes Mellituss Type2 580 581 http://www.endometabol.com/index.php?page=article&article_id=7929 Fereidoun Azizi Fereidoun Azizi Wowocrknei~wwmuwwm go~te~losw{oerskimnsu{|uwmanov Golosz}oeuke~smw} nammdicelesk}mnwo{~ero~ybo~:mu}{{um4ww{ences, IR Iran +98-2122409309, azizi@endocrine.ac.ir; Wowocrknei~wwmuwwm go~te~losw{oerskimnsu{|uwmanov Golosz}oeuke~smw} nammdicelesk}mnwo{~ero~ybo~:mu}{{um4ww{ences, IR Iran +98-2122409309, azizi@endocrine.ac.ir Wowocrknei~wwmuwwm go~te~losw{oerskimnsu{|uwmanov Golosz}oeuke~smw} nammdicelesk}mnwo{~ero~ybo~:mu}{{um4ww{ences, IR Iran +98-2122409309, azizi@endocrine.ac.ir; Wowocrknei~wwmuwwm go~te~losw{oerskimnsu{|uwmanov Golosz}oeuke~smw} nammdicelesk}mnwo{~ero~ybo~:mu}{{um4ww{ences, IR Iran +98-2122409309, azizi@endocrine.ac.ir
en 10.5812/ijem.5029 Reduced Antioxidant Potential of LDL Is Associated With Increased Susceptibility to LDL Peroxidation in Type II Diabetic Patients Reduced Antioxidant Potential of LDL Is Associated With Increased Susceptibility to LDL Peroxidation in Type II Diabetic Patients research-article research-article Conclusions

In type II diabetes, the increased susceptibility of LDL to oxidation is related to hyperglycemia and low AOP.

Background

Type II diabetes mellitus is a complex heterogeneous group of metabolic conditions characterized by an increased level of blood glucose, due to impairment in insulin action and/or insulin secretion. Hyperglycemia is a major factor in the pathogenesis of atherosclerosis in diabetes. Oxidative modification of low density lipoprotein (LDL) is recognized as one of the major processes involved in the early stages of atherosclerosis in type II diabetes. LDL contains different antioxidants, which increase LDL resistance against oxidative modification, this is known as its antioxidant potential (AOP).

Objectives

The present study has been carried out to investigate the sensitivity of LDL to oxidation, AOP of LDL and to assess whether hyperglycemia in diabetes mellitus is associated with increased LDL oxidizability, and whether these relationships are related to diabetic complications.

Patients and Methods

This study was carried out on 100 diabetic subjects, divided into two groups according to their glycosylated hemoglobin (HbA1c) values, either regulated ( < 0.50 M hexose/ M Hb) or unregulated ( > 0.50 M hexose/ M Hb.) A further 50 healthy subjects were included to determine the sensitivity of LDL oxidation and measurement of LDL AOP. LDL from the serum sample was precipitated by the heparin-citrate precipitation method. The LDL fractions were exposed to oxidation with copper sulphate and their sensitivity to oxidation was evaluated. AOP was measured by taking measurements from 30 subjects in each group.

Results

The sensitivity of LDL oxidation was significantly higher in both diabetic groups compared to the control group. AOP was significantly decreased in all diabetic groups compared to the control group.

Conclusions

In type II diabetes, the increased susceptibility of LDL to oxidation is related to hyperglycemia and low AOP.

Background

Type II diabetes mellitus is a complex heterogeneous group of metabolic conditions characterized by an increased level of blood glucose, due to impairment in insulin action and/or insulin secretion. Hyperglycemia is a major factor in the pathogenesis of atherosclerosis in diabetes. Oxidative modification of low density lipoprotein (LDL) is recognized as one of the major processes involved in the early stages of atherosclerosis in type II diabetes. LDL contains different antioxidants, which increase LDL resistance against oxidative modification, this is known as its antioxidant potential (AOP).

Objectives

The present study has been carried out to investigate the sensitivity of LDL to oxidation, AOP of LDL and to assess whether hyperglycemia in diabetes mellitus is associated with increased LDL oxidizability, and whether these relationships are related to diabetic complications.

Patients and Methods

This study was carried out on 100 diabetic subjects, divided into two groups according to their glycosylated hemoglobin (HbA1c) values, either regulated ( < 0.50 M hexose/ M Hb) or unregulated ( > 0.50 M hexose/ M Hb.) A further 50 healthy subjects were included to determine the sensitivity of LDL oxidation and measurement of LDL AOP. LDL from the serum sample was precipitated by the heparin-citrate precipitation method. The LDL fractions were exposed to oxidation with copper sulphate and their sensitivity to oxidation was evaluated. AOP was measured by taking measurements from 30 subjects in each group.

Results

The sensitivity of LDL oxidation was significantly higher in both diabetic groups compared to the control group. AOP was significantly decreased in all diabetic groups compared to the control group.

Diabetes Mellitus;LDL Oxidation Sensitivity;Antioxidant Potential (AOP) Diabetes Mellitus;LDL Oxidation Sensitivity;Antioxidant Potential (AOP) 582 586 http://www.endometabol.com/index.php?page=article&article_id=5029 Nivedita Singh Nivedita Singh Department of Biochemistry, GR Medical College, India +91-9098299972, niveditagrmc@rediffmail.com; Department of Biochemistry, GR Medical College, India +91-9098299972, niveditagrmc@rediffmail.com Department of Biochemistry, GR Medical College, India +91-9098299972, niveditagrmc@rediffmail.com; Department of Biochemistry, GR Medical College, India +91-9098299972, niveditagrmc@rediffmail.com Neelima Singh Neelima Singh Department of Biochemistry, GR Medical College, India +91-9098299972, niveditagrmc@rediffmail.com Department of Biochemistry, GR Medical College, India +91-9098299972, niveditagrmc@rediffmail.com Sanjeev Kumar Kumar Singh Sanjeev Kumar Kumar Singh Department of Biochemistry, GR Medical College, India +91-9098299972, niveditagrmc@rediffmail.com Department of Biochemistry, GR Medical College, India +91-9098299972, niveditagrmc@rediffmail.com Ajay Kumar Kumar Singh Ajay Kumar Kumar Singh Department of Biochemistry, GR Medical College, India +91-9098299972, niveditagrmc@rediffmail.com Department of Biochemistry, GR Medical College, India +91-9098299972, niveditagrmc@rediffmail.com Deepak kafle Deepak kafle Department of Biochemistry, GR Medical College, India +91-9098299972, niveditagrmc@rediffmail.com Department of Biochemistry, GR Medical College, India +91-9098299972, niveditagrmc@rediffmail.com Navneet Agrawal Navneet Agrawal Department of Biochemistry, GR Medical College, India +91-9098299972, niveditagrmc@rediffmail.com Department of Biochemistry, GR Medical College, India +91-9098299972, niveditagrmc@rediffmail.com
en 10.5812/ijem.4783 Postprandial Peaking and Plateauing of Triglycerides and VLDL in Patients with Underlying Cardiovascular Diseases Despite Treatment Postprandial Peaking and Plateauing of Triglycerides and VLDL in Patients with Underlying Cardiovascular Diseases Despite Treatment research-article research-article Background

Dyslipidemia is associated with cardiovascular morbidities and mortality. Currently, fasting lipid profile determination is used to monitor treatment response. Recently, postprandial lipemia is of increasing interest because of its atherogenic and thrombogenic potential and also was found to be more predictive for cardiovascular diseases.

Objectives

To demonstrate postprandial lipemia among patients with cardiovascular diseases despite low fat diet, normal fasting lipid profile and even statin regimen.

Patients and Methods

Patients aged 40-80 years old with cardiovascular diseases (i.e. coronary artery disease and cerebrovascular disease) more than 6 months, on statin treatment for more than 6 months and normal fasting lipid profile (according to NCEP ATP III guidelines) were included. Study exclusion criteria were pregnancy, acute cardiovascular events < 6 months, hepatic or renal failure. Finally, twelve patients were included.

Results

The triglyceride level showed a significant rise from fasting to 2 hours after breakfast with a mean difference of 23.86 mg/dL (P =0.012). The level peaked at 4 hours after breakfast with a mean difference (MD) of 72.02 mg/dL (P =0.002). Subsequent triglyceride levels plateaued and were significantly higher than the baseline (P <0.05) until the 12th hour of observation. VLDL levels showed a similar pattern. Levels increased significantly from fasting to 2h after breakfast (mean difference: 4.49 mg/dL, P = 0.007), then plateaued and further increased 4 hours after breakfast (MD: 14.01 mg/dL, P = 0.002). VLDL levels were significantly higher than fasting (P < 0.05) and did not return to baseline until the 12th hour of observation. In contrast, the levels of total cholesterol, HDL and LDL decreased postprandially.

Conclusions

Triglyceride and VLDL peaking and plateauing were observed in patients with cardiovascular diseases despite low fat diet, normal fasting lipid profile and statin regimen. These findings may raise more attentions in monitoring and management of dyslipidemia in patients with cardiovascular and cerebrovascular events.

Background

Dyslipidemia is associated with cardiovascular morbidities and mortality. Currently, fasting lipid profile determination is used to monitor treatment response. Recently, postprandial lipemia is of increasing interest because of its atherogenic and thrombogenic potential and also was found to be more predictive for cardiovascular diseases.

Objectives

To demonstrate postprandial lipemia among patients with cardiovascular diseases despite low fat diet, normal fasting lipid profile and even statin regimen.

Patients and Methods

Patients aged 40-80 years old with cardiovascular diseases (i.e. coronary artery disease and cerebrovascular disease) more than 6 months, on statin treatment for more than 6 months and normal fasting lipid profile (according to NCEP ATP III guidelines) were included. Study exclusion criteria were pregnancy, acute cardiovascular events < 6 months, hepatic or renal failure. Finally, twelve patients were included.

Results

The triglyceride level showed a significant rise from fasting to 2 hours after breakfast with a mean difference of 23.86 mg/dL (P =0.012). The level peaked at 4 hours after breakfast with a mean difference (MD) of 72.02 mg/dL (P =0.002). Subsequent triglyceride levels plateaued and were significantly higher than the baseline (P <0.05) until the 12th hour of observation. VLDL levels showed a similar pattern. Levels increased significantly from fasting to 2h after breakfast (mean difference: 4.49 mg/dL, P = 0.007), then plateaued and further increased 4 hours after breakfast (MD: 14.01 mg/dL, P = 0.002). VLDL levels were significantly higher than fasting (P < 0.05) and did not return to baseline until the 12th hour of observation. In contrast, the levels of total cholesterol, HDL and LDL decreased postprandially.

Conclusions

Triglyceride and VLDL peaking and plateauing were observed in patients with cardiovascular diseases despite low fat diet, normal fasting lipid profile and statin regimen. These findings may raise more attentions in monitoring and management of dyslipidemia in patients with cardiovascular and cerebrovascular events.

Postprandial Lipemia;Cardiovasular Disease;Triglyceride;VLDL Postprandial Lipemia;Cardiovasular Disease;Triglyceride;VLDL 587 593 http://www.endometabol.com/index.php?page=article&article_id=4783 Clarissa E. E. Samson Clarissa E. E. Samson Section of Endocrinology and Metabolism, University of Santo Tomas Hospital, Philippines +63-27313046, leilanimercadoasis@endo-society.org.ph Section of Endocrinology and Metabolism, University of Santo Tomas Hospital, Philippines +63-27313046, leilanimercadoasis@endo-society.org.ph Ana Lyza B. B. Galia Ana Lyza B. B. Galia Section of Endocrinology and Metabolism, University of Santo Tomas Hospital, Philippines +63-27313046, leilanimercadoasis@endo-society.org.ph Section of Endocrinology and Metabolism, University of Santo Tomas Hospital, Philippines +63-27313046, leilanimercadoasis@endo-society.org.ph Khristine Ivy C. C. Llave Khristine Ivy C. C. Llave Dietary Services, University of Santo Tomas Hospital, Philippines Dietary Services, University of Santo Tomas Hospital, Philippines Manuel B. B. Zacarias Manuel B. B. Zacarias Section of Cardiology, University of Santo Tomas Hospital, Philippines Section of Cardiology, University of Santo Tomas Hospital, Philippines Leilani B. B. Mercado-Asis Leilani B. B. Mercado-Asis Section of Endocrinology and Metabolism, University of Santo Tomas Hospital, Philippines +63-27313046, leilanimercadoasis@endo-society.org.ph; Section of Endocrinology and Metabolism, University of Santo Tomas Hospital, Philippines +63-27313046, leilanimercadoasis@endo-society.org.ph Section of Endocrinology and Metabolism, University of Santo Tomas Hospital, Philippines +63-27313046, leilanimercadoasis@endo-society.org.ph; Section of Endocrinology and Metabolism, University of Santo Tomas Hospital, Philippines +63-27313046, leilanimercadoasis@endo-society.org.ph
en 10.5812/ijem.3462 Serum Intact Parathyroid Hormone Level After Total Thyroidectomy or Total Thyroidectomy Plus Lymph Node Dissection for Thyroid Nodules: Report From 296 Surgical Cases Serum Intact Parathyroid Hormone Level After Total Thyroidectomy or Total Thyroidectomy Plus Lymph Node Dissection for Thyroid Nodules: Report From 296 Surgical Cases research-article research-article Background

Transient hypocalcemia is one of the postoperative complications of thyroidectomy for thyroid nodules, and intraoperative and postoperative intact parathyroid hormone (iPTH) assays are used to predict postoperative hypocalcemia.

Objectives

The current study was conducted to evaluate a single serum iPTH measurement on postoperative day 1 (POD 1) as a means to predict hypocalcemia occurrence after total thyroidectomy (TT).

Patients and Methods

The subjects consisted of 36 patients who underwent TT and 260 patients who underwent TT plus lymph node (LN) dissection for thyroid nodules treatment. The TT performance procedure to prevent postoperative hypoparathyroidism combines parathyroid gland preservation in situ with autotransplantation of resected or devascularized parathyroid glands. The patients’ serum iPTH level was measured on POD 1, and their serum calcium level was measured on POD 1 and on POD 3 while they were still inpatients. The serum iPTH level was subequently measured at each outpatient clinic visit until it recovered to the normal range.

Results

Hypoparathyroidism after TT and TT plus LN dissection was ultimately diagnosed in a total of 229 patients, and in 69 of them hypocalcemia was diagnosed on POD 1. All of the 69 patients diagnosed with hypocalcemia received calcium and vitamin D supplementation therapy. The serum iPTH level of 67 of 229 patients was within normal range on POD 1, and four of them developed hypocalcemia on POD 1. Permanent hypoparathyroidism developed in 37 of 296 patients after undergoing TT or TT plus LN dissection for thyroid nodules in the hospital.

Conclusions

A single serum iPTH measurement on POD 1 is useful to determine whether or not to start calcium and vitamin D supplementation in order to maintain normocalcemia after surgery.

Background

Transient hypocalcemia is one of the postoperative complications of thyroidectomy for thyroid nodules, and intraoperative and postoperative intact parathyroid hormone (iPTH) assays are used to predict postoperative hypocalcemia.

Objectives

The current study was conducted to evaluate a single serum iPTH measurement on postoperative day 1 (POD 1) as a means to predict hypocalcemia occurrence after total thyroidectomy (TT).

Patients and Methods

The subjects consisted of 36 patients who underwent TT and 260 patients who underwent TT plus lymph node (LN) dissection for thyroid nodules treatment. The TT performance procedure to prevent postoperative hypoparathyroidism combines parathyroid gland preservation in situ with autotransplantation of resected or devascularized parathyroid glands. The patients’ serum iPTH level was measured on POD 1, and their serum calcium level was measured on POD 1 and on POD 3 while they were still inpatients. The serum iPTH level was subequently measured at each outpatient clinic visit until it recovered to the normal range.

Results

Hypoparathyroidism after TT and TT plus LN dissection was ultimately diagnosed in a total of 229 patients, and in 69 of them hypocalcemia was diagnosed on POD 1. All of the 69 patients diagnosed with hypocalcemia received calcium and vitamin D supplementation therapy. The serum iPTH level of 67 of 229 patients was within normal range on POD 1, and four of them developed hypocalcemia on POD 1. Permanent hypoparathyroidism developed in 37 of 296 patients after undergoing TT or TT plus LN dissection for thyroid nodules in the hospital.

Conclusions

A single serum iPTH measurement on POD 1 is useful to determine whether or not to start calcium and vitamin D supplementation in order to maintain normocalcemia after surgery.

Hypoparathyroidism;Hypocalcemia;Thyroidectomy, Thyroid Nodule;Parathyroid Hypoparathyroidism;Hypocalcemia;Thyroidectomy, Thyroid Nodule;Parathyroid 594 598 http://www.endometabol.com/index.php?page=article&article_id=3462 Yukiko Yano Yukiko Yano Ito Hospital, 4-3-6 Jinngumae, Shibuya, Japan +81-334027411, y-yano@itohospital. jp; Ito Hospital, 4-3-6 Jinngumae, Shibuya, Japan +81-334027411, y-yano@itohospital. jp Ito Hospital, 4-3-6 Jinngumae, Shibuya, Japan +81-334027411, y-yano@itohospital. jp; Ito Hospital, 4-3-6 Jinngumae, Shibuya, Japan +81-334027411, y-yano@itohospital. jp Chie Masaki Chie Masaki Ito Hospital, 4-3-6 Jinngumae, Shibuya, Japan +81-334027411, y-yano@itohospital. jp Ito Hospital, 4-3-6 Jinngumae, Shibuya, Japan +81-334027411, y-yano@itohospital. jp Kiminori Sugino Kiminori Sugino Ito Hospital, 4-3-6 Jinngumae, Shibuya, Japan +81-334027411, y-yano@itohospital. jp Ito Hospital, 4-3-6 Jinngumae, Shibuya, Japan +81-334027411, y-yano@itohospital. jp Mitsuji Nagahama Mitsuji Nagahama Ito Hospital, 4-3-6 Jinngumae, Shibuya, Japan +81-334027411, y-yano@itohospital. jp Ito Hospital, 4-3-6 Jinngumae, Shibuya, Japan +81-334027411, y-yano@itohospital. jp Wataru Kitagawa Wataru Kitagawa Ito Hospital, 4-3-6 Jinngumae, Shibuya, Japan +81-334027411, y-yano@itohospital. jp Ito Hospital, 4-3-6 Jinngumae, Shibuya, Japan +81-334027411, y-yano@itohospital. jp Hiroshi Sibuya Hiroshi Sibuya Ito Hospital, 4-3-6 Jinngumae, Shibuya, Japan +81-334027411, y-yano@itohospital. jp Ito Hospital, 4-3-6 Jinngumae, Shibuya, Japan +81-334027411, y-yano@itohospital. jp Koichi Ito Koichi Ito Ito Hospital, 4-3-6 Jinngumae, Shibuya, Japan +81-334027411, y-yano@itohospital. jp Ito Hospital, 4-3-6 Jinngumae, Shibuya, Japan +81-334027411, y-yano@itohospital. jp
en 10.5812/ijem.4967 Bone density in patients with late onset Pompe disease Bone density in patients with late onset Pompe disease research-article research-article Background

Pompe disease is an inherited metabolic disorder characterized by α-glycosidase deficiency, which leads to lysosomal glycogen accumulation in many different tissues. The infantile form is the most severe with a rapidly fatal outcome, while the late onset form has a greater phenotypic variability, characterized by skeletal muscle dysfunction and early respiratory involvement. Bone mineral density (BMD) has been recently reported to be reduced in many patients with both forms of the disease. Enzyme replacement therapy (ERT) is now available with an undefined, impact on BMD in patients with late onset disease.

Objectives

The present study aimed to investigate BMD in patients with late onset form of Pompe disease before and after ERT initiation.

Patients and Methods

Dual x-ray absorptiometry (DEXA) was examined in four newly diagnosed patients with late onset Pompe disease and in four adults under ERT before and after ERT initiation with a treatment duration of 18 to 36 months.

Results

The initial DEXA showed normal total body BMD z-score in all the patients, while L2-L4 and femoral neck BMD was reduced in three and two patients, respectively. After ERT administration, two patients had an improvement in L2-L4 lumbar spine and one patient in femoral neck BMD z-score with values within normal range.

Conclusions

The results suggested that regional BMD may moderately reduce in some patients with the late onset form of Pompe disease, although profound osteopenia was not observed. The improvement of measurements in L2-L4 and femoral neck BMD z-score in some patients with low pre-treatment values after ERT administration needs to be confirmed in larger scale studies.

Background

Pompe disease is an inherited metabolic disorder characterized by α-glycosidase deficiency, which leads to lysosomal glycogen accumulation in many different tissues. The infantile form is the most severe with a rapidly fatal outcome, while the late onset form has a greater phenotypic variability, characterized by skeletal muscle dysfunction and early respiratory involvement. Bone mineral density (BMD) has been recently reported to be reduced in many patients with both forms of the disease. Enzyme replacement therapy (ERT) is now available with an undefined, impact on BMD in patients with late onset disease.

Objectives

The present study aimed to investigate BMD in patients with late onset form of Pompe disease before and after ERT initiation.

Patients and Methods

Dual x-ray absorptiometry (DEXA) was examined in four newly diagnosed patients with late onset Pompe disease and in four adults under ERT before and after ERT initiation with a treatment duration of 18 to 36 months.

Results

The initial DEXA showed normal total body BMD z-score in all the patients, while L2-L4 and femoral neck BMD was reduced in three and two patients, respectively. After ERT administration, two patients had an improvement in L2-L4 lumbar spine and one patient in femoral neck BMD z-score with values within normal range.

Conclusions

The results suggested that regional BMD may moderately reduce in some patients with the late onset form of Pompe disease, although profound osteopenia was not observed. The improvement of measurements in L2-L4 and femoral neck BMD z-score in some patients with low pre-treatment values after ERT administration needs to be confirmed in larger scale studies.

Bone Density;α-glucosidase;Pompe Disease Bone Density;α-glucosidase;Pompe Disease 599 603 http://www.endometabol.com/index.php?page=article&article_id=4967 George Papadimas George Papadimas Uoywwvm~} of Ou}woog{ohomvovsmu}ioone|huw,dwsimeov ogdog}~ologmnmwiootiopis|ital, 74, Vas. Sophias Ave, Greece +30-2107289152, gkpapad@yahoo.gr; Uoywwvm~} of Ou}woog{ohomvovsmu}ioone|huw,dwsimeov ogdog}~ologmnmwiootiopis|ital, 74, Vas. Sophias Ave, Greece +30-2107289152, gkpapad@yahoo.gr Uoywwvm~} of Ou}woog{ohomvovsmu}ioone|huw,dwsimeov ogdog}~ologmnmwiootiopis|ital, 74, Vas. Sophias Ave, Greece +30-2107289152, gkpapad@yahoo.gr; Uoywwvm~} of Ou}woog{ohomvovsmu}ioone|huw,dwsimeov ogdog}~ologmnmwiootiopis|ital, 74, Vas. Sophias Ave, Greece +30-2107289152, gkpapad@yahoo.gr Gerassimos Terzis Gerassimos Terzis Uoywwvm~} of Ou}woog{ohomvovsmu}ioone|huw,dwsimeov ogdog}~ologmnmwiootiopis|ital, 74, Vas. Sophias Ave, Greece +30-2107289152, gkpapad@yahoo.gr; Athletics Laboratory, School of Physical Education and Sport Science, University of Athens, Greece Uoywwvm~} of Ou}woog{ohomvovsmu}ioone|huw,dwsimeov ogdog}~ologmnmwiootiopis|ital, 74, Vas. Sophias Ave, Greece +30-2107289152, gkpapad@yahoo.gr; Athletics Laboratory, School of Physical Education and Sport Science, University of Athens, Greece Constantinos Papadopoulos Constantinos Papadopoulos Uoywwvm~} of Ou}woog{ohomvovsmu}ioone|huw,dwsimeov ogdog}~ologmnmwiootiopis|ital, 74, Vas. Sophias Ave, Greece +30-2107289152, gkpapad@yahoo.gr Uoywwvm~} of Ou}woog{ohomvovsmu}ioone|huw,dwsimeov ogdog}~ologmnmwiootiopis|ital, 74, Vas. Sophias Ave, Greece +30-2107289152, gkpapad@yahoo.gr Anna Areovimata Anna Areovimata Uoywwvm~} of Ou}woog{ohomvovsmu}ioone|huw,dwsimeov ogdog}~ologmnmwiootiopis|ital, 74, Vas. Sophias Ave, Greece +30-2107289152, gkpapad@yahoo.gr Uoywwvm~} of Ou}woog{ohomvovsmu}ioone|huw,dwsimeov ogdog}~ologmnmwiootiopis|ital, 74, Vas. Sophias Ave, Greece +30-2107289152, gkpapad@yahoo.gr Konstantinos Spengos Konstantinos Spengos Uoywwvm~} of Ou}woog{ohomvovsmu}ioone|huw,dwsimeov ogdog}~ologmnmwiootiopis|ital, 74, Vas. Sophias Ave, Greece +30-2107289152, gkpapad@yahoo.gr Uoywwvm~} of Ou}woog{ohomvovsmu}ioone|huw,dwsimeov ogdog}~ologmnmwiootiopis|ital, 74, Vas. Sophias Ave, Greece +30-2107289152, gkpapad@yahoo.gr Stavros Kavouras Stavros Kavouras Laboratory of Nutrition and Clinical Dietetics, Harokopio University of Athens, Greece Laboratory of Nutrition and Clinical Dietetics, Harokopio University of Athens, Greece Panagiota Manta Panagiota Manta Uoywwvm~} of Ou}woog{ohomvovsmu}ioone|huw,dwsimeov ogdog}~ologmnmwiootiopis|ital, 74, Vas. Sophias Ave, Greece +30-2107289152, gkpapad@yahoo.gr Uoywwvm~} of Ou}woog{ohomvovsmu}ioone|huw,dwsimeov ogdog}~ologmnmwiootiopis|ital, 74, Vas. Sophias Ave, Greece +30-2107289152, gkpapad@yahoo.gr
en 10.5812/ijem.5305 ABCG8 Gene Responses to 8 Weeks Treadmill Running With or Without Pistachia atlantica (Baneh) Extraction in Female Rats ABCG8 Gene Responses to 8 Weeks Treadmill Running With or Without Pistachia atlantica (Baneh) Extraction in Female Rats research-article research-article Background

It is well established that the excess cellular cholesterol concentration, as well as high density lipoprotein (HDL) and total cholesterol levels are strongly correlated with the incidence of coronary artery disease (CAD). Reverse cholesterol transport (RCT) is a term used to describe the efflux of excess cellular cholesterol. ABCG8 is a member of ABCG family that play a critical role in this process.

Objectives

The current study was conducted to investigate the effect of endurance exercise with or without Pistachia atlantica (Baneh) extraction on small intestine and kidney ABCG8 gene, also plasma high density lipoprotein (HDL-c), triglyceride (TG), total cholesterol (TC), glucose, and estrogen levels in female rats.

Materials and Methods

In this study twenty Wistar female rats (six to eight weeks old, 125-135 g weight) were used. Animals were randomly assigned into training (n = 10) and control (n = 10) groups and further divided into saline-control (SC), saline-training (ST), Baneh-control (BC), and Baneh-training (BT) groups. Training groups was given exercise on a motor-driven treadmill at 25 m/min (0% grade) for 60 min/day, 5 days/week for eight weeks. Animals were fed orally with Baneh extraction and saline for four week. After the last training session, rats were sacrificed, small intestine and kidney were excised, and ABCG8 expression was detected by Real-time PCR method. Plasma also was collected for plasma variable measurements. Statistical analysis was performed using a one way analysis of variance, and significance was accepted at P < 0.05. Correlation was calculated using the Pearson Product Moment correlation.

Results

Exercise increased (P < 0.01) and Baneh reduced intestinal ABCG8 mRNA (P < 0.05). In kidney tissue, there wasn’t significant change between the groups (P < 0.40). Plasma HDL-C level was increased by exercise (P < 0.05) and decreased by Baneh (P < 0.02) that was correlated by intestine ABCG8 (r = 0.81, P < 0.001). Plasma TG and TC were unchanged, but glucose and estradiol were increased and decreased in Baneh groups (P < 0.02), respectively.

Conclusions

Our study shows that exercise increases intestinal ABCG8 mRNA, and Baneh can increase plasma glucose concentration and reduce ABCG8 expression, HDL-C, and estrogen levels probably due to high fatty acid components.

Background

It is well established that the excess cellular cholesterol concentration, as well as high density lipoprotein (HDL) and total cholesterol levels are strongly correlated with the incidence of coronary artery disease (CAD). Reverse cholesterol transport (RCT) is a term used to describe the efflux of excess cellular cholesterol. ABCG8 is a member of ABCG family that play a critical role in this process.

Objectives

The current study was conducted to investigate the effect of endurance exercise with or without Pistachia atlantica (Baneh) extraction on small intestine and kidney ABCG8 gene, also plasma high density lipoprotein (HDL-c), triglyceride (TG), total cholesterol (TC), glucose, and estrogen levels in female rats.

Materials and Methods

In this study twenty Wistar female rats (six to eight weeks old, 125-135 g weight) were used. Animals were randomly assigned into training (n = 10) and control (n = 10) groups and further divided into saline-control (SC), saline-training (ST), Baneh-control (BC), and Baneh-training (BT) groups. Training groups was given exercise on a motor-driven treadmill at 25 m/min (0% grade) for 60 min/day, 5 days/week for eight weeks. Animals were fed orally with Baneh extraction and saline for four week. After the last training session, rats were sacrificed, small intestine and kidney were excised, and ABCG8 expression was detected by Real-time PCR method. Plasma also was collected for plasma variable measurements. Statistical analysis was performed using a one way analysis of variance, and significance was accepted at P < 0.05. Correlation was calculated using the Pearson Product Moment correlation.

Results

Exercise increased (P < 0.01) and Baneh reduced intestinal ABCG8 mRNA (P < 0.05). In kidney tissue, there wasn’t significant change between the groups (P < 0.40). Plasma HDL-C level was increased by exercise (P < 0.05) and decreased by Baneh (P < 0.02) that was correlated by intestine ABCG8 (r = 0.81, P < 0.001). Plasma TG and TC were unchanged, but glucose and estradiol were increased and decreased in Baneh groups (P < 0.02), respectively.

Conclusions

Our study shows that exercise increases intestinal ABCG8 mRNA, and Baneh can increase plasma glucose concentration and reduce ABCG8 expression, HDL-C, and estrogen levels probably due to high fatty acid components.

Treadmill Running;ABCG8;Pistachia Atlantica;Female;Rat Treadmill Running;ABCG8;Pistachia Atlantica;Female;Rat 604 610 http://www.endometabol.com/index.php?page=article&article_id=5305 Abbass Ghanbari-Niaki Abbass Ghanbari-Niaki Department of Physical Education and Sport Science, University of Mazandaran, IR Iran +98- 9111256292, ghanbara@umz.ac.ir; Department of Physical Education and Sport Science, University of Mazandaran, IR Iran +98- 9111256292, ghanbara@umz.ac.ir Department of Physical Education and Sport Science, University of Mazandaran, IR Iran +98- 9111256292, ghanbara@umz.ac.ir; Department of Physical Education and Sport Science, University of Mazandaran, IR Iran +98- 9111256292, ghanbara@umz.ac.ir Saleh Rahmati- Ahmadabad Saleh Rahmati- Ahmadabad Department of Physical Education and Sport Science, University of Mazandaran, IR Iran +98- 9111256292, ghanbara@umz.ac.ir Department of Physical Education and Sport Science, University of Mazandaran, IR Iran +98- 9111256292, ghanbara@umz.ac.ir Navabeh Zare- Kookandeh Navabeh Zare- Kookandeh Department of Physical Education and Sport Science, University of Mazandaran, IR Iran +98- 9111256292, ghanbara@umz.ac.ir Department of Physical Education and Sport Science, University of Mazandaran, IR Iran +98- 9111256292, ghanbara@umz.ac.ir
en 10.5812/ijem.4020 Cardiovascular Risk in Women With PCOS Cardiovascular Risk in Women With PCOS review-article review-article

Polycystic ovary syndrome (PCOS), or Stein-Leventhal syndrome, is a common endocrine disorder defined by two of the three following features: i) oligoovulation or anovulation, ii) clinical and/or biochemical signs of hyperandrogenism, or iii) polycystic ovaries, once the related endocrinological and gynaecological disorders have been excluded. PCOS does not exclusively involve the reproductive apparatus , it has a complex number of systemic relevancy symptoms. It leads to Metabolic Syndrome, with severe consequences on the cardiovascular apparatus. Many clinical studies have underlined the connection between PCOS and the cardiovascular risk profile of such female patients, due to a lipid/glucose altered metabolism, hypertension, systemic inflammatory condition (assessable by markers such as VES, TNF-alfa, citokines and C-reactive protein (hsPCR) levels), and vascular injuries. Considering the early onset of the disease, PCOS could be considered as a real cardiovascular risk factor which affects the quality of life seriously. The current review aimed to point out the main connections between PCOS and cardiovascular risk factors according to the latest findings coming from literature data analysis, and try to depict the great influences that such a common disease can have on the patients’ health integrity.

Polycystic ovary syndrome (PCOS), or Stein-Leventhal syndrome, is a common endocrine disorder defined by two of the three following features: i) oligoovulation or anovulation, ii) clinical and/or biochemical signs of hyperandrogenism, or iii) polycystic ovaries, once the related endocrinological and gynaecological disorders have been excluded. PCOS does not exclusively involve the reproductive apparatus , it has a complex number of systemic relevancy symptoms. It leads to Metabolic Syndrome, with severe consequences on the cardiovascular apparatus. Many clinical studies have underlined the connection between PCOS and the cardiovascular risk profile of such female patients, due to a lipid/glucose altered metabolism, hypertension, systemic inflammatory condition (assessable by markers such as VES, TNF-alfa, citokines and C-reactive protein (hsPCR) levels), and vascular injuries. Considering the early onset of the disease, PCOS could be considered as a real cardiovascular risk factor which affects the quality of life seriously. The current review aimed to point out the main connections between PCOS and cardiovascular risk factors according to the latest findings coming from literature data analysis, and try to depict the great influences that such a common disease can have on the patients’ health integrity.

PCOS;Cardiovascular Risk;Metabolic Syndrome;Diabetes;Hypertension PCOS;Cardiovascular Risk;Metabolic Syndrome;Diabetes;Hypertension 611 618 http://www.endometabol.com/index.php?page=article&article_id=4020 Pietro Scicchitano Pietro Scicchitano Section of Cardiovascular Diseases, Deto~t}oovewiu}egenc{imnwcoomnovrmowyoinumtyonmc}oogivyron Ris{~asgnoomsovemuuioiu=2toliclinico, Italy +39-0805478791, ciccone@cardio.uniba.it Section of Cardiovascular Diseases, Deto~t}oovewiu}egenc{imnwcoomnovrmowyoinumtyonmc}oogivyron Ris{~asgnoomsovemuuioiu=2toliclinico, Italy +39-0805478791, ciccone@cardio.uniba.it Ilaria Dentamaro Ilaria Dentamaro Section of Cardiovascular Diseases, Deto~t}oovewiu}egenc{imnwcoomnovrmowyoinumtyonmc}oogivyron Ris{~asgnoomsovemuuioiu=2toliclinico, Italy +39-0805478791, ciccone@cardio.uniba.it Section of Cardiovascular Diseases, Deto~t}oovewiu}egenc{imnwcoomnovrmowyoinumtyonmc}oogivyron Ris{~asgnoomsovemuuioiu=2toliclinico, Italy +39-0805478791, ciccone@cardio.uniba.it Rosa Carbonara Rosa Carbonara Section of Cardiovascular Diseases, Deto~t}oovewiu}egenc{imnwcoomnovrmowyoinumtyonmc}oogivyron Ris{~asgnoomsovemuuioiu=2toliclinico, Italy +39-0805478791, ciccone@cardio.uniba.it Section of Cardiovascular Diseases, Deto~t}oovewiu}egenc{imnwcoomnovrmowyoinumtyonmc}oogivyron Ris{~asgnoomsovemuuioiu=2toliclinico, Italy +39-0805478791, ciccone@cardio.uniba.it Gabriella Bulzis Gabriella Bulzis Section of Cardiovascular Diseases, Deto~t}oovewiu}egenc{imnwcoomnovrmowyoinumtyonmc}oogivyron Ris{~asgnoomsovemuuioiu=2toliclinico, Italy +39-0805478791, ciccone@cardio.uniba.it Section of Cardiovascular Diseases, Deto~t}oovewiu}egenc{imnwcoomnovrmowyoinumtyonmc}oogivyron Ris{~asgnoomsovemuuioiu=2toliclinico, Italy +39-0805478791, ciccone@cardio.uniba.it Annamaria Dachille Annamaria Dachille Section of Cardiovascular Diseases, Deto~t}oovewiu}egenc{imnwcoomnovrmowyoinumtyonmc}oogivyron Ris{~asgnoomsovemuuioiu=2toliclinico, Italy +39-0805478791, ciccone@cardio.uniba.it Section of Cardiovascular Diseases, Deto~t}oovewiu}egenc{imnwcoomnovrmowyoinumtyonmc}oogivyron Ris{~asgnoomsovemuuioiu=2toliclinico, Italy +39-0805478791, ciccone@cardio.uniba.it Paola Caputo Paola Caputo Section of Cardiovascular Diseases, Deto~t}oovewiu}egenc{imnwcoomnovrmowyoinumtyonmc}oogivyron Ris{~asgnoomsovemuuioiu=2toliclinico, Italy +39-0805478791, ciccone@cardio.uniba.it Section of Cardiovascular Diseases, Deto~t}oovewiu}egenc{imnwcoomnovrmowyoinumtyonmc}oogivyron Ris{~asgnoomsovemuuioiu=2toliclinico, Italy +39-0805478791, ciccone@cardio.uniba.it Roberta Riccardi Roberta Riccardi Section of Cardiovascular Diseases, Deto~t}oovewiu}egenc{imnwcoomnovrmowyoinumtyonmc}oogivyron Ris{~asgnoomsovemuuioiu=2toliclinico, Italy +39-0805478791, ciccone@cardio.uniba.it Section of Cardiovascular Diseases, Deto~t}oovewiu}egenc{imnwcoomnovrmowyoinumtyonmc}oogivyron Ris{~asgnoomsovemuuioiu=2toliclinico, Italy +39-0805478791, ciccone@cardio.uniba.it Manuela Locorotondo Manuela Locorotondo Section of Cardiovascular Diseases, Deto~t}oovewiu}egenc{imnwcoomnovrmowyoinumtyonmc}oogivyron Ris{~asgnoomsovemuuioiu=2toliclinico, Italy +39-0805478791, ciccone@cardio.uniba.it Section of Cardiovascular Diseases, Deto~t}oovewiu}egenc{imnwcoomnovrmowyoinumtyonmc}oogivyron Ris{~asgnoomsovemuuioiu=2toliclinico, Italy +39-0805478791, ciccone@cardio.uniba.it Cosimo Mandurino Cosimo Mandurino Section of Cardiovascular Diseases, Deto~t}oovewiu}egenc{imnwcoomnovrmowyoinumtyonmc}oogivyron Ris{~asgnoomsovemuuioiu=2toliclinico, Italy +39-0805478791, ciccone@cardio.uniba.it Section of Cardiovascular Diseases, Deto~t}oovewiu}egenc{imnwcoomnovrmowyoinumtyonmc}oogivyron Ris{~asgnoomsovemuuioiu=2toliclinico, Italy +39-0805478791, ciccone@cardio.uniba.it Marco Matteo Matteo Ciccone Marco Matteo Matteo Ciccone Section of Cardiovascular Diseases, Deto~t}oovewiu}egenc{imnwcoomnovrmowyoinumtyonmc}oogivyron Ris{~asgnoomsovemuuioiu=2toliclinico, Italy +39-0805478791, ciccone@cardio.uniba.it; Section of Cardiovascular Diseases, Deto~t}oovewiu}egenc{imnwcoomnovrmowyoinumtyonmc}oogivyron Ris{~asgnoomsovemuuioiu=2toliclinico, Italy +39-0805478791, ciccone@cardio.uniba.it Section of Cardiovascular Diseases, Deto~t}oovewiu}egenc{imnwcoomnovrmowyoinumtyonmc}oogivyron Ris{~asgnoomsovemuuioiu=2toliclinico, Italy +39-0805478791, ciccone@cardio.uniba.it; Section of Cardiovascular Diseases, Deto~t}oovewiu}egenc{imnwcoomnovrmowyoinumtyonmc}oogivyron Ris{~asgnoomsovemuuioiu=2toliclinico, Italy +39-0805478791, ciccone@cardio.uniba.it
en 10.5812/ijem.4510 Von Hippel-Lindau Disease: A New Approach to an Old Problem Von Hippel-Lindau Disease: A New Approach to an Old Problem review-article review-article Background

Von Hippel-Lindau (VHL) disease is a hereditary, autosomal dominant syndrome which is manifested by a range of different benign and malignant tumors. This disease can present with different clinical presentations such as; retinal angioma (RA), hemangioblastoma (HB) of the central nervous system (CNS), pheochromocytoma (Pheo), and epididymal cystadenoma. Tumors are usually accompanied with cysts.

Objectives

As the disease can display different clinical presentations, which are mainly unspecific, and considering the importance of an early diagnosis and the proper and early management of it, this study was carried out to present a general overview of VHL. Moreover, the present article reviews screening methods and emphasizes the need for increasing the awareness of different health care professionals to diagnose and refer the patients in the early stages.

Materials and Methods

A thorough search of internet medical databases, such as PubMed, was carried out on known or suggested; clinical presentations, pathogenesis, screening, causes and criteria for diagnosis of patients and their referrals.

Results

Our research demonstrated that VHL is caused by a mutation in the von Hippel-Lindau (VHL) gene. It also showed that different screening methods can be utilized for the early diagnosis and referral of patients. Different clinical presentations of the disease are also elaborated in some detail and their treatment options are discussed.

Conclusions

Considering the need for a multidisciplinary approach to VHL, especially, given the number of cases which have been reported and diagnosed in Iran, it is of great importance that clinicians remain vigilant in order to identify cases that present with clinical characteristics of the disease, and that they are prompt in referring them to a multidisciplinary VHL clinic. It is also important to establish links with existing VHL Family Alliances and other related organizations around the world.

Background

Von Hippel-Lindau (VHL) disease is a hereditary, autosomal dominant syndrome which is manifested by a range of different benign and malignant tumors. This disease can present with different clinical presentations such as; retinal angioma (RA), hemangioblastoma (HB) of the central nervous system (CNS), pheochromocytoma (Pheo), and epididymal cystadenoma. Tumors are usually accompanied with cysts.

Objectives

As the disease can display different clinical presentations, which are mainly unspecific, and considering the importance of an early diagnosis and the proper and early management of it, this study was carried out to present a general overview of VHL. Moreover, the present article reviews screening methods and emphasizes the need for increasing the awareness of different health care professionals to diagnose and refer the patients in the early stages.

Materials and Methods

A thorough search of internet medical databases, such as PubMed, was carried out on known or suggested; clinical presentations, pathogenesis, screening, causes and criteria for diagnosis of patients and their referrals.

Results

Our research demonstrated that VHL is caused by a mutation in the von Hippel-Lindau (VHL) gene. It also showed that different screening methods can be utilized for the early diagnosis and referral of patients. Different clinical presentations of the disease are also elaborated in some detail and their treatment options are discussed.

Conclusions

Considering the need for a multidisciplinary approach to VHL, especially, given the number of cases which have been reported and diagnosed in Iran, it is of great importance that clinicians remain vigilant in order to identify cases that present with clinical characteristics of the disease, and that they are prompt in referring them to a multidisciplinary VHL clinic. It is also important to establish links with existing VHL Family Alliances and other related organizations around the world.

Von Hippel-Lindau Disease;Pheochromocytoma Von Hippel-Lindau Disease;Pheochromocytoma 619 624 http://www.endometabol.com/index.php?page=article&article_id=4510 Ali Tootee Ali Tootee Uolc~iomg{sot}egbomm{oa~esgiwoke{nsuotwwmn|ogloov,mw|arom}{mhwsmusol Oostituwoashavmmty4ywpital, IR Iran +98-2188220037, sh_hasani@sina.tums.ac.ir Uolc~iomg{sot}egbomm{oa~esgiwoke{nsuotwwmn|ogloov,mw|arom}{mhwsmusol Oostituwoashavmmty4ywpital, IR Iran +98-2188220037, sh_hasani@sina.tums.ac.ir Shirin Hasani- Ranjbar Shirin Hasani- Ranjbar Uolc~iomg{sot}egbomm{oa~esgiwoke{nsuotwwmn|ogloov,mw|arom}{mhwsmusol Oostituwoashavmmty4ywpital, IR Iran +98-2188220037, sh_hasani@sina.tums.ac.ir; Uolc~iomg{sot}egbomm{oa~esgiwoke{nsuotwwmn|ogloov,mw|arom}{mhwsmusol Oostituwoashavmmty4ywpital, IR Iran +98-2188220037, sh_hasani@sina.tums.ac.ir Uolc~iomg{sot}egbomm{oa~esgiwoke{nsuotwwmn|ogloov,mw|arom}{mhwsmusol Oostituwoashavmmty4ywpital, IR Iran +98-2188220037, sh_hasani@sina.tums.ac.ir; Uolc~iomg{sot}egbomm{oa~esgiwoke{nsuotwwmn|ogloov,mw|arom}{mhwsmusol Oostituwoashavmmty4ywpital, IR Iran +98-2188220037, sh_hasani@sina.tums.ac.ir
en 10.5812/ijem.5406 Recombinant TSH and Lithium Overcomes Amiodarone-Induced Low Radioiodine Uptake in a Thyrotoxic Female Recombinant TSH and Lithium Overcomes Amiodarone-Induced Low Radioiodine Uptake in a Thyrotoxic Female case-report case-report Introduction:

Recombinant human thyroid-stimulating hormone(rhTSH) increases radioactive iodine uptake(RAIU) in selected populations, while lithium is used as an adjunct to radioactive iodine (RAI) therapy in Graves’ disease with low RAIU. In this report, both drugs used in combination, overcame low iodine-131 uptake in a Graves’ patient.

Clinical Case:

A 39-year old female with Graves’ disease, acquired thionamide-induced agranulocytosis, and severe hypokalemia, subsequently went into cardiorespiratory arrest. On resuscitation, she had ventricular tachyarrhythmias which were cardioverted using amiodarone. She was subsequently placed on IV hydrocortisone amiodarone and propranolol. On admission, she was normotensive, tachycardic, and afebrile. She had fine tremors, hyper reflexia, and diffuse, non-tender thyromegaly. Initial investigations showed normal complete blood count, hypokalemia and elevated alanine transaminase levels. Levels of thyroid stimulating hormone were low (0.03 uIU/L, N = 0.27-3.75). Thyroid ultrasound showed diffuse thyromegaly with uniform echopattern and normal color flow Doppler, radioiodine uptake showed low uptake at 0400h and 2400h (6% and 7%, respectively). In preparation for RAI therapy, she was given lithium 900mg/day for 12 days to increase RAI retention. To increase iodine-131 uptake, two doses of 0.9mg rhTSH were injected intramuscular, 24 hours apart, before RAI therapy. Repeat RAIU after the second dose of rhTSH showed more than a 5-fold increase in 0400h uptake compared with the baseline (32% vs. 6%). Exactly 24 hours after the second dose of rhTSH, she was given 25mCi of iodine-131. Thereafter, the patient’s clinical and biochemical markers continued to improve. She became hypothyroid and is currently on levothyroxine replacement therapy.

Conclusions:

This case demonstrates the efficacy of combining rhTSH and lithium to overcome amiodarone-induced low iodine-131 uptake in Graves’ disease.

Introduction:

Recombinant human thyroid-stimulating hormone(rhTSH) increases radioactive iodine uptake(RAIU) in selected populations, while lithium is used as an adjunct to radioactive iodine (RAI) therapy in Graves’ disease with low RAIU. In this report, both drugs used in combination, overcame low iodine-131 uptake in a Graves’ patient.

Clinical Case:

A 39-year old female with Graves’ disease, acquired thionamide-induced agranulocytosis, and severe hypokalemia, subsequently went into cardiorespiratory arrest. On resuscitation, she had ventricular tachyarrhythmias which were cardioverted using amiodarone. She was subsequently placed on IV hydrocortisone amiodarone and propranolol. On admission, she was normotensive, tachycardic, and afebrile. She had fine tremors, hyper reflexia, and diffuse, non-tender thyromegaly. Initial investigations showed normal complete blood count, hypokalemia and elevated alanine transaminase levels. Levels of thyroid stimulating hormone were low (0.03 uIU/L, N = 0.27-3.75). Thyroid ultrasound showed diffuse thyromegaly with uniform echopattern and normal color flow Doppler, radioiodine uptake showed low uptake at 0400h and 2400h (6% and 7%, respectively). In preparation for RAI therapy, she was given lithium 900mg/day for 12 days to increase RAI retention. To increase iodine-131 uptake, two doses of 0.9mg rhTSH were injected intramuscular, 24 hours apart, before RAI therapy. Repeat RAIU after the second dose of rhTSH showed more than a 5-fold increase in 0400h uptake compared with the baseline (32% vs. 6%). Exactly 24 hours after the second dose of rhTSH, she was given 25mCi of iodine-131. Thereafter, the patient’s clinical and biochemical markers continued to improve. She became hypothyroid and is currently on levothyroxine replacement therapy.

Conclusions:

This case demonstrates the efficacy of combining rhTSH and lithium to overcome amiodarone-induced low iodine-131 uptake in Graves’ disease.

rhTSH;Lithium;Amiodarone rhTSH;Lithium;Amiodarone 625 628 http://www.endometabol.com/index.php?page=article&article_id=5406 Nestor Eric R. Laplano Nestor Eric R. Laplano Suot}oomow Eoeogvmoooo}esnd2oetgnoo{m}n}~mvw{wytfowauoto}oa{o{{ti|mlEspana, Philippines +632-7313001, nerlmd@yahoo.com; Suot}oomow Eoeogvmoooo}esnd2oetgnoo{m}n}~mvw{wytfowauoto}oa{o{{ti|mlEspana, Philippines +632-7313001, nerlmd@yahoo.com Suot}oomow Eoeogvmoooo}esnd2oetgnoo{m}n}~mvw{wytfowauoto}oa{o{{ti|mlEspana, Philippines +632-7313001, nerlmd@yahoo.com; Suot}oomow Eoeogvmoooo}esnd2oetgnoo{m}n}~mvw{wytfowauoto}oa{o{{ti|mlEspana, Philippines +632-7313001, nerlmd@yahoo.com Leilani B. Mercado-Asis Leilani B. Mercado-Asis Suot}oomow Eoeogvmoooo}esnd2oetgnoo{m}n}~mvw{wytfowauoto}oa{o{{ti|mlEspana, Philippines +632-7313001, nerlmd@yahoo.com Suot}oomow Eoeogvmoooo}esnd2oetgnoo{m}n}~mvw{wytfowauoto}oa{o{{ti|mlEspana, Philippines +632-7313001, nerlmd@yahoo.com
en 10.5812/ijem.4313 Diagnosis of Men-I Syndrome on 68Ga-DOTANOC PET-CT and Role of Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE Diagnosis of Men-I Syndrome on <sup>68</sup>Ga-DOTANOC PET-CT and Role of Peptide Receptor Radionuclide Therapy With <sup>177</sup>Lu-DOTATATE case-report case-report Abstract

MEN-I is a rare genetic disorder classically characterized by a predisposition to tumors of the parathyroid glands, anterior pituitary gland, and pancreatic islet cells. We present a case of MEN-I syndrome diagnosed using predominantly nuclear medicine imaging followed by radionuclide therapy, thus emphasizing the role of nuclear imaging in diagnosing and treating MEN-I.

Abstract

MEN-I is a rare genetic disorder classically characterized by a predisposition to tumors of the parathyroid glands, anterior pituitary gland, and pancreatic islet cells. We present a case of MEN-I syndrome diagnosed using predominantly nuclear medicine imaging followed by radionuclide therapy, thus emphasizing the role of nuclear imaging in diagnosing and treating MEN-I.

Multiple Endocrine Neoplasia-I;Nuclear Imaging Multiple Endocrine Neoplasia-I;Nuclear Imaging 629 633 http://www.endometabol.com/index.php?page=article&article_id=4313 Santosh kumar Gupta Santosh kumar Gupta Department of Nuclear Medicine, All India Institute of Medical Sciences, India +91-1126593530, santoshaiims@gmail.com; Department of Nuclear Medicine, All India Institute of Medical Sciences, India +91-1126593530, santoshaiims@gmail.com Department of Nuclear Medicine, All India Institute of Medical Sciences, India +91-1126593530, santoshaiims@gmail.com; Department of Nuclear Medicine, All India Institute of Medical Sciences, India +91-1126593530, santoshaiims@gmail.com Suhas Singla Suhas Singla Department of Nuclear Medicine, All India Institute of Medical Sciences, India +91-1126593530, santoshaiims@gmail.com Department of Nuclear Medicine, All India Institute of Medical Sciences, India +91-1126593530, santoshaiims@gmail.com Nishikant A Damle Nishikant A Damle Department of Nuclear Medicine, All India Institute of Medical Sciences, India +91-1126593530, santoshaiims@gmail.com Department of Nuclear Medicine, All India Institute of Medical Sciences, India +91-1126593530, santoshaiims@gmail.com Krishankant Agarwal Krishankant Agarwal Department of Nuclear Medicine, All India Institute of Medical Sciences, India +91-1126593530, santoshaiims@gmail.com Department of Nuclear Medicine, All India Institute of Medical Sciences, India +91-1126593530, santoshaiims@gmail.com Chandersekhar Bal Chandersekhar Bal Department of Nuclear Medicine, All India Institute of Medical Sciences, India +91-1126593530, santoshaiims@gmail.com Department of Nuclear Medicine, All India Institute of Medical Sciences, India +91-1126593530, santoshaiims@gmail.com
en 10.5812/ijem.6239 Are Physicians Ready to Prevent Osteoporotic Fractures in Hemodialysis Patients? Are Physicians Ready to Prevent Osteoporotic Fractures in Hemodialysis Patients? letter letter Osteoporotic Fractures;Hemodialysis Patients Osteoporotic Fractures;Hemodialysis Patients 634 635 http://www.endometabol.com/index.php?page=article&article_id=6239 Antonino Lasco Antonino Lasco Department of Internal Medicine, Uno~u~sy}ioniomsiG. Martino” Via C. Valeria, Italy +39-0902212391, alasco@unime.it; Department of Internal Medicine, Uno~u~sy}ioniomsiG. Martino” Via C. Valeria, Italy +39-0902212391, alasco@unime.it Department of Internal Medicine, Uno~u~sy}ioniomsiG. Martino” Via C. Valeria, Italy +39-0902212391, alasco@unime.it; Department of Internal Medicine, Uno~u~sy}ioniomsiG. Martino” Via C. Valeria, Italy +39-0902212391, alasco@unime.it Antonino Catalano Antonino Catalano Department of Internal Medicine, Uno~u~sy}ioniomsiG. Martino” Via C. Valeria, Italy +39-0902212391, alasco@unime.it Department of Internal Medicine, Uno~u~sy}ioniomsiG. Martino” Via C. Valeria, Italy +39-0902212391, alasco@unime.it Nancy Morabito Nancy Morabito Department of Internal Medicine, Uno~u~sy}ioniomsiG. Martino” Via C. Valeria, Italy +39-0902212391, alasco@unime.it Department of Internal Medicine, Uno~u~sy}ioniomsiG. Martino” Via C. Valeria, Italy +39-0902212391, alasco@unime.it
en 10.5812/ijem.6251 Significant Effect of Raloxifene on Bone in Hemodialysis Patients Significant Effect of Raloxifene on Bone in Hemodialysis Patients letter letter Raloxifene;Hemodialysis Patients Raloxifene;Hemodialysis Patients 636 637 http://www.endometabol.com/index.php?page=article&article_id=6251 Pernille Ravn Pernille Ravn Department of Gynecology and Obstetrics, Gynecologic-Endocrinology Unit, Odense University Hospital, Denmark +45-65411260, pernille.ravn@ouh.regionsyddanmark.dk; Department of Gynecology and Obstetrics, Gynecologic-Endocrinology Unit, Odense University Hospital, Denmark +45-65411260, pernille.ravn@ouh.regionsyddanmark.dk Department of Gynecology and Obstetrics, Gynecologic-Endocrinology Unit, Odense University Hospital, Denmark +45-65411260, pernille.ravn@ouh.regionsyddanmark.dk; Department of Gynecology and Obstetrics, Gynecologic-Endocrinology Unit, Odense University Hospital, Denmark +45-65411260, pernille.ravn@ouh.regionsyddanmark.dk
en 10.5812/ijem.6285 Safety of Raloxifene in Hemodialysis Patients Safety of Raloxifene in Hemodialysis Patients letter letter Raloxifene;Hemodialysis Raloxifene;Hemodialysis 638 639 http://www.endometabol.com/index.php?page=article&article_id=6285 Didy Jacobsen Didy Jacobsen Geriatric Department, Radboud University Medical Center, The Netherlands +31-243616772, d.jacobsen@ger.umcn.nl; Geriatric Department, Radboud University Medical Center, The Netherlands +31-243616772, d.jacobsen@ger.umcn.nl Geriatric Department, Radboud University Medical Center, The Netherlands +31-243616772, d.jacobsen@ger.umcn.nl; Geriatric Department, Radboud University Medical Center, The Netherlands +31-243616772, d.jacobsen@ger.umcn.nl
en 10.5812/ijem.5384 Preventing Fractures in Diabetic Dialysis Patients Preventing Fractures in Diabetic Dialysis Patients letter letter Osteoporosis;Treatment;Chronic Kidney Disease;Diabetes Mellitus Osteoporosis;Treatment;Chronic Kidney Disease;Diabetes Mellitus 640 641 http://www.endometabol.com/index.php?page=article&article_id=5384 E. Michael Lewiecki E. Michael Lewiecki New Mexico Clinical Research & Osteoporosis Center, s|ruuorsuo NE, Albuquerque, USA +505-8555525, lewiecki@aol.com; New Mexico Clinical Research & Osteoporosis Center, s|ruuorsuo NE, Albuquerque, USA +505-8555525, lewiecki@aol.com New Mexico Clinical Research & Osteoporosis Center, s|ruuorsuo NE, Albuquerque, USA +505-8555525, lewiecki@aol.com; New Mexico Clinical Research & Osteoporosis Center, s|ruuorsuo NE, Albuquerque, USA +505-8555525, lewiecki@aol.com
en 10.5812/ijem.5394 Which Method is More Efficient in Determining Osteoporosis, QUS or DEXA? Which Method is More Efficient in Determining Osteoporosis, QUS or DEXA? letter letter Osteoporosis;Bone Mineral Density Osteoporosis;Bone Mineral Density 642 643 http://www.endometabol.com/index.php?page=article&article_id=5394 Cem Dane Cem Dane Lese{}mu~uioongyoogo~ow}asol Oostmtsmoslexasuomntroonooecolow}seovcob{wt{}c, Turkey +90-212 6217521, cemdane@yahoo.com; Lese{}mu~uioongyoogo~ow}asol Oostmtsmoslexasuomntroonooecolow}seovcob{wt{}c, Turkey +90-212 6217521, cemdane@yahoo.com Lese{}mu~uioongyoogo~ow}asol Oostmtsmoslexasuomntroonooecolow}seovcob{wt{}c, Turkey +90-212 6217521, cemdane@yahoo.com; Lese{}mu~uioongyoogo~ow}asol Oostmtsmoslexasuomntroonooecolow}seovcob{wt{}c, Turkey +90-212 6217521, cemdane@yahoo.com Banu Dane Banu Dane Department of Gynecology and Obstetrics, Bezmialem University, Faculty of Medicine, Turkey Department of Gynecology and Obstetrics, Bezmialem University, Faculty of Medicine, Turkey
en 10.5812/ijem.6580 Raloxifene May Have Further Benefits in Women on Hemodialysis Raloxifene May Have Further Benefits in Women on Hemodialysis letter letter Raloxifene;Mood;Dialysis Raloxifene;Mood;Dialysis 644 645 http://www.endometabol.com/index.php?page=article&article_id=6580 Roisin Worsley Roisin Worsley Monash Alfred Psychiatry Research Centre, Monash University, Australia +44-39076 6294, r.worsley@alfred.org.au; Monash Alfred Psychiatry Research Centre, Monash University, Australia +44-39076 6294, r.worsley@alfred.org.au Monash Alfred Psychiatry Research Centre, Monash University, Australia +44-39076 6294, r.worsley@alfred.org.au; Monash Alfred Psychiatry Research Centre, Monash University, Australia +44-39076 6294, r.worsley@alfred.org.au Emorfia Gavrilidis Emorfia Gavrilidis Monash Alfred Psychiatry Research Centre, Monash University, Australia +44-39076 6294, r.worsley@alfred.org.au Monash Alfred Psychiatry Research Centre, Monash University, Australia +44-39076 6294, r.worsley@alfred.org.au Jayashri Kulkarni Jayashri Kulkarni Monash Alfred Psychiatry Research Centre, Monash University, Australia +44-39076 6294, r.worsley@alfred.org.au Monash Alfred Psychiatry Research Centre, Monash University, Australia +44-39076 6294, r.worsley@alfred.org.au
en 10.5812/ijem.6558 Effects of Raloxifene on Bone in Patients With Type 2 Diabetes Effects of Raloxifene on Bone in Patients With Type 2 Diabetes letter letter Type 2 Diabetes;Raloxifene;Hemodialysis Type 2 Diabetes;Raloxifene;Hemodialysis 646 647 http://www.endometabol.com/index.php?page=article&article_id=6558 Itsuo Gorai Itsuo Gorai Department of Obstetrics and Gynecology, Hori Hospital, v}vavwucus}kmsho-c{o}ao}a-ku, Japan ; Department of Obstetrics and Gynecology, Hori Hospital, v}vavwucus}kmsho-c{o}ao}a-ku, Japan Department of Obstetrics and Gynecology, Hori Hospital, v}vavwucus}kmsho-c{o}ao}a-ku, Japan ; Department of Obstetrics and Gynecology, Hori Hospital, v}vavwucus}kmsho-c{o}ao}a-ku, Japan